The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Just come on to the board for the first time in a while. I was was hoping to find some discussion on yesterdays RNS re: NEWCREST now owning 10.30% of the shares. But found the board full of rubbish, 80 hits and price resistance discussion???
Very surprised Blue Orca have published this info following the RNS dated 17 February 2023 regarding Minerals Income Investment Fund "MIIF" of GHANA wanting to invest $30M in the company. A Ghana investment fund would know of any corruption in its own country before starting negotiating with ALL! Hopefully the next RNS from ALL will highlight this.
The balance sheet is impressive. 183 Million in Current Assets against an MCAP of just over £100 Million. This gives the company a chance to grow and prosper. They have a plan. Long term investors will be rewarded.
At the end of June our half year figures, we had Net Assets of £138.5M and cash at £77M. We have grown cash to £102M. So lets say net assets year end come in £163.5M. We currently have an MCAP around £46.5M below Net Assets of the business? If we can generate £50M a year with a profit of £20M per year for the next 3 years and somebody puts a valuation of 10X Profit + Assets gives you what my valuation of this business is worth. £163.5M + £200M= £363.5M. + £40M (DHSC Dispute Owing) £403.5M. Divide this by the current MCAP and times the current share price you get a share price of 569. Maybe more as health and diagnostics usually achieve a higher multiple. Share price will rise again once investors take a good look at the fundamentals.
Well undervalued. Patience needed but will come back. Take a look at the half year figures from 30th June 21. We had Net Assets of £138.5M. Cash was £77M. We now have cash at £102M. Add the difference and we get Net Assets of £163.5M. So the current MCAP is below the Net Assets of the company??? The SP is not currently reflecting future growth and profits? Patience required but current SP is way off.
My filters gone into overdrive. Lots of green which usually means paid 50p de-rampers trying to take the share down. Take a look at the half year accounts and EFK as a comparison and you will soon see the fundamentals don't match the MCAP. The MCAP suggests this business has no value or will not generate value in the future? I think it will!
Down here heavily, however if you look at the Net Current Assets at 6 months to June 2021 we have a figure of £138.5M. The current MCAP is £139M. If you add say another £25M cash since that date you have Net Current Assets of £164M. So the current MCAP is trading well below Net Current Assets and gives no value to the business what so ever? Are we saying this business is not worth anything going forward? I don't think so? DYOH
Not saying its Novacyt, but there is UK diagnostic company out there really ramping up production. I wonder which one?
https://www.shropshirestar.com/news/business/2022/01/06/450-jobs-on-offer-to-help-covid-fight-in-telford/
My view is that the majority of PCR tests sold by Novacyt are to organisations who still need to guard against Covid, eg hospitals, Pharma, care homes etc. These sales will continue regardless and will show in the next round of figures to be published.
I'm getting updates direct now from the company. The one below was sent on the 15th Dec. Surprised there has not been an RNS this month?
At Novacyt Group, we pride ourselves on the scientific rigour we apply to all aspects of product design. As the COVID-19 pandemic continues to develop, ongoing analysis becomes increasingly crucial. Our state-of-the-art SARS-CoV-2 genomic surveillance programme allows us to monitor the virus closely as it spreads and mutates. We are pleased to report the latest findings for our solutions:
SNPsig® SARS-CoV-2 EscapePLEX can be used to screen SARS-CoV-2 positive samples for the presence of the Omicron variant with >98% confidence.
PathFlow® COVID-19 Rapid Antigen Pro targets the nucleocapsid protein (NP) of the SARS-CoV-2 virus, and therefore unaffected by the mutations associated with Omicron (BA.1 & BA.2), and other Variants of Concern (VoC).
Novacyt’s other main qPCR assays intended for primary SARS-CoV-2 testing are unaffected by the emergence of the Omicron variant.
Lots of information in todays video for investors. Dr Anthony Cooke expecting new restrictions and lft tests just for screening. Missing variants using just lft!
Quote from Dr Cooke, "If you are going to test do it properly with PCR".
Gemma Stokes from Novacyt said they are developing the Winterplex product.
Heavily invested in Novacyt. So like a lot of investors very disappointed with the share price. I'm not invested in EFK, however I have been looking at their web site and figures as a comparison. The information below gives me confidence that the Novacyt MCAP is worth a lot more.
Take a read of the information below, I'm sure you will agree by selling your shares now you will be kicking yourself in 3-6-12 months time.
H1 2021 performance
Full year performance expected to be in-line with management expectations
EKF Diagnostics Holdings plc (AIM: EKF), the?AIM listed point-of-care business, provides the following trading update for the six months ended 30 June 2021.
As previously announced in our AGM statement in May, the strong trading from the beginning of the year continued into the second quarter of 2021. This continues to reflect improving trading in the core business and ongoing strong demand for our contract manufacturing services for COVID-19 sample collection devices and associated kits. The Board remains confident that trading for the full year will remain strong and will be in-line with already materially upgraded management expectations.
Revenues for the six months ended 30 June 2021 were £38.56m (H1 2020: £26.33m) and the Company expects to report adjusted EBITDA1 in the region of £12.75m (H1 2020: £8.93m).
Gross cash as at 30 June 2021 was £20.78m and cash net of borrowings was £20.39m, in-line with management expectations. In addition, the Company’s interest in Renalytix plc (1,002,981 shares) had a fair value of £10.83m, and its Verici Dx plc securities (2,677,981 shares) had a fair value of £1.83m, based on closing mid-market prices on 30 June 2021.
Following the payment of an inaugural cash dividend of 1p per share at the end of last year (in respect of 2019) the Company has confirmed its intention to maintain a modest but progressive dividend policy, and a further dividend payment to shareholders of 1.1p per ordinary share, which it proposes to pay on 1 December 2021 to shareholders on the register at the close of business on 5 November 2021. The ex-dividend date for this timetable is 4 November 2021.
The Company remains confident that its growth strategy, as outlined to shareholders at the Annual General Meeting in May, will create a business which, aside from any COVID-19 related revenues, is capable of generating significant double-digit growth in adjusted EBITDA1 over the next 3 to 4 years. The Board believe this can be achieved by:
investing in the existing core business to drive strong organic growth;
maximising value from the agreement with Mount Sinai Innovation Partners;
seeking complementary and targeted earnings-enhancing acquisitions with key strategic value to the core business;
continuing to maximise the opportunity to assist clients to control the impact of COVID-19, and to evolve new contract manufacturing capabilities in this area to a broader range of diagnostic and other health
If the media start getting hold of the fact the the government is not paying for goods received and owe millions to several UK diagnostic companies, some of which have had to make people redundant then we might see the DHSC dispute resolved sooner than later. This government won't want more bad news! Hopefully the dispute will soon be sorted and we can move on.
Long term partnership developing with Dam including other diagnostic products, none Covid related. Paragragh below taken from Business Desk. Over the long term this has to be a positive for the company.
While the initial agreement centres around the VISITECT professional Antigen LFTs, there is the possibility to broaden the partnership to include Omega’s VISITECT Antigen self-test LFT, once approved. Further talks are also exploring a distribution agreement to sell Omega’s health and nutrition products (Food Detective) throughout DAM Health’s network.
Thank you Kaeren, great video. Gives me more confidence in my investment. Novacyt will be a major player in the diagnostic business going forward. The SP will eventually catch up with the fact that we are a growing business. We have many solutions and exciting products which are selling, plus a good reputation in the market place. Would be nice to see UK PLC start to get behind British companies like Novacyt to push us forward.